• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals.

作者信息

Kawedia Jitesh D, Rausch Caitlin R, Liu Xiaoqian, Qiao Wei, Dinardo Courtney D, Daver Naval, Borthakur Gautam, Pemmaraju Naveen, Reville Patrick, Kontoyiannis Dimitrios P, Short Nicholas, Konopleva Marina, Jabbour Elias, Garcia-Manero Guillermo, Ravandi Farhad, Kantarjian Hagop, Kadia Tapan M

机构信息

Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

出版信息

Am J Hematol. 2025 Apr;100(4):740-743. doi: 10.1002/ajh.27613. Epub 2025 Jan 28.

DOI:10.1002/ajh.27613
PMID:39873236
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11888890/
Abstract
摘要

相似文献

1
Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals.维奈托克在急性髓系白血病中的前瞻性药代动力学评估支持重新评估与唑类抗真菌药联用的推荐剂量调整。
Am J Hematol. 2025 Apr;100(4):740-743. doi: 10.1002/ajh.27613. Epub 2025 Jan 28.
2
Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia.联合唑类抗真菌药物与维奈托克联合阿扎胞苷治疗新诊断的急性髓系白血病患者。
Hematology. 2024 Dec;29(1):2433172. doi: 10.1080/16078454.2024.2433172. Epub 2024 Nov 25.
3
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.伴有 venetoclax 和唑类抗真菌药物的急性髓系白血病患者的细胞减少持续时间。
Cancer. 2021 Jul 15;127(14):2489-2499. doi: 10.1002/cncr.33508. Epub 2021 Apr 1.
4
Remission rate, toxicity and pharmacokinetics of venetoclax-based induction regimens in untreated pediatric acute myeloid leukemia.基于维奈托克的诱导方案在初治儿童急性髓系白血病中的缓解率、毒性和药代动力学
NPJ Precis Oncol. 2024 Nov 2;8(1):248. doi: 10.1038/s41698-024-00740-5.
5
Drug interactions of tacrolimus with letermovir and azole antifungals following hematopoietic stem cell transplantation: A retrospective observational analysis.他克莫司与来特莫韦和唑类抗真菌药在造血干细胞移植后的药物相互作用：一项回顾性观察性分析。
Pharmacol Res Perspect. 2023 Aug;11(4):e01120. doi: 10.1002/prp2.1120.
6
Dosing of Venetoclax in Pediatric Patients with Relapsed Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships. Venetoclax 在复发急性髓系白血病儿科患者中的剂量：发育药代动力学和暴露-反应关系分析。
Clin Ther. 2024 Oct;46(10):759-767. doi: 10.1016/j.clinthera.2024.09.008. Epub 2024 Oct 5.
7
Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia.基于维奈克拉方案治疗急性髓系白血病的真实单中心经验。
Front Oncol. 2023 Mar 27;13:1149298. doi: 10.3389/fonc.2023.1149298. eCollection 2023.
8
Physiologically based pharmacokinetic modeling to predict the clinical effect of azole antifungal agents as CYP3A inhibitors on azelnidipine pharmacokinetics.基于生理学的药代动力学模型预测唑类抗真菌药物作为 CYP3A 抑制剂对阿齐利特药代动力学的临床影响。
Drug Metab Pharmacokinet. 2024 Apr;55:101000. doi: 10.1016/j.dmpk.2024.101000. Epub 2024 Jan 23.
9
Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.细胞遗传学和突变可预测接受 BCL-2 抑制剂 venetoclax 的复发/难治性急性髓系白血病患者的结局。
Ann Hematol. 2020 Mar;99(3):501-511. doi: 10.1007/s00277-020-03911-z. Epub 2020 Jan 21.
10
Pharmacokinetics of Azole Antifungals in Cystic Fibrosis.唑类抗真菌药物在囊性纤维化中的药代动力学。
Mycopathologia. 2018 Feb;183(1):139-150. doi: 10.1007/s11046-017-0189-6. Epub 2017 Aug 9.

引用本文的文献

1
Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia.新诊断急性髓系白血病的八九十岁老人的当代治疗结果
Cancer. 2025 Aug 15;131(16):e70028. doi: 10.1002/cncr.70028.
2
Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes: a retrospective study.维奈托克联合低甲基化药物治疗骨髓增生异常综合征的暴露-反应分析：一项回顾性研究
Front Pharmacol. 2025 Jul 14;16:1586910. doi: 10.3389/fphar.2025.1586910. eCollection 2025.
3
A Population Pharmacokinetics Study of Venetoclax Concomitant with Voriconazole in Patients with Hematologic Malignancies.维奈克拉与伏立康唑联用在血液系统恶性肿瘤患者中的群体药代动力学研究。
Drug Des Devel Ther. 2025 May 5;19:3681-3690. doi: 10.2147/DDDT.S514173. eCollection 2025.

本文引用的文献

1
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.伴有 venetoclax 和唑类抗真菌药物的急性髓系白血病患者的细胞减少持续时间。
Cancer. 2021 Jul 15;127(14):2489-2499. doi: 10.1002/cncr.33508. Epub 2021 Apr 1.
2
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
3
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.优化新型老年急性髓系白血病患者联合低强度治疗方案中的维奈托克剂量：暴露反应分析。
Hematol Oncol. 2019 Oct;37(4):464-473. doi: 10.1002/hon.2646. Epub 2019 Aug 2.
4
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.成人癌症相关免疫抑制患者的抗菌预防：ASCO 和 IDSA 临床实践指南更新。
J Clin Oncol. 2018 Oct 20;36(30):3043-3054. doi: 10.1200/JCO.18.00374. Epub 2018 Sep 4.
5
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.急性髓系白血病患者中维奈克拉与泊沙康唑相互作用的管理：剂量调整评估
Clin Ther. 2017 Feb;39(2):359-367. doi: 10.1016/j.clinthera.2017.01.003. Epub 2017 Feb 1.
6
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.泊沙康唑与氟康唑或伊曲康唑对中性粒细胞减少患者的预防作用比较
N Engl J Med. 2007 Jan 25;356(4):348-59. doi: 10.1056/NEJMoa061094.